TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22969201
Drug: Faringel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faringel (10 mL)
Study: 19958532
Drug: CVVH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVVH at 4 L/h for 60 min then 2 L/h
Study: 19958532
Drug: CVVH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVVH at 2 L/h for 60 min then 4 L/h
Study: 17332197
Drug: Delayed cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cord clamping (60 to 90 seconds) with maternal administration of syntocinon
Study: 7994616
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (CPT) and sub-therapeutic doses of cyclosporine A (CsA) at 2mg/kg/d
Study: 23446684
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg/day
Study: 23446684
Drug: Pridopidine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine (combined 45 mg/day and 90 mg/day)
Study: 12809962
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg/kg IV
Study: 9212119
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 10 mg every 6 h for up to 3 days
Study: 9212119
Drug: Hydrocodone 7.5
Normalized name: HYDROCODONE 7.5/IBUPROFEN 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 7.5 mg plus acetaminophen 750 mg every 6 h for up to 3 days
Study: 9212119
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules followed by ketorolac 10 mg every 6 h for up to 3 days
Study: 31491535
Drug: Retrieval of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrieval of online Problem‐Solving Therapy (PST) sessions
Study: 31491535
Drug: Rehearsal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehearsal of online Problem‐Solving Therapy (PST) sessions
Study: 26116425
Drug: Erdosteine 900
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 900 mg/day
Study: 26116425
Drug: Erdosteine 600
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 600 mg/day
Study: 23860343
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg infusion
Study: 21663622
Drug: Standard macronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard macronutrient content (maximum protein 2.8 g/kg/day; lipid 2.8 g/kg/day, dextrose 10%)
Study: 21663622
Drug: Higher macronutrient
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher macronutrient content (maximum protein 3.8 g/kg/day; lipid 3.8 g/kg/day, dextrose 12%)
Study: 16598443
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg orally before PCI, uptitrated to 50 mg daily)
Study: 16598443
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg orally before PCI, uptitrated to 150 mg daily)
Study: 9430864
Drug: HighBic. (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HighBic. (40 mmol/l) bicarbonate dialysate
Study: 9430864
Drug: LowBic. (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LowBic. (30 mmol/l) bicarbonate dialysate
Study: 3799495
Drug: Pumpkin-seed supplementation
Normalized name: PUMPKIN SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpkin-seed supplementation 60 mg X kg body wt-1 X day-1
Study: 3799495
Drug: Orthophosphate supplementation
Normalized name: FERRIC ORTHOPHOSPHATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthophosphate supplementation 60 mg X kg body wt-1 X day-1
Study: 3799495
Drug: Oxalate supplementation
Normalized name: oxalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalate supplementation 5 mg X kg-1 body wt X day-1
Study: 6731261
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before treatment)
Study: 27483038
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + Vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Study: 15711271
Drug: Ketoconazole (KT)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KT) plus hydrocortisone (H) plus alendronate (AL) (1,200 mg daily KT, 30 mg daily H, 40 mg daily AL)
Study: 15711271
Drug: Ketoconazole (KT)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KT) plus hydrocortisone (H) (1,200 mg daily KT, 30 mg daily H)
Study: 8843295
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 mg daily for 14 days)
Study: 3881051
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg of oral physostigmine
Study: 3881051
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of oral physostigmine
Study: 3881051
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of oral physostigmine
Study: 3881051
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of oral physostigmine
Study: 3881051
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg of oral physostigmine
Study: 3881051
Drug: Dose associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose associated with least severe symptoms
Study: 24660159
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (15 mg/kg)
Study: 23522247
Drug: lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine treatment (n=164)
Study: 18671947
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (calcium plus A. senticosus)
Study: 15986343
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for 30 months
Study: 12566640
Drug: 10% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucrose rinse, 5 times daily
Study: 12566640
Drug: 10% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucrose rinse, 10 times daily
Study: 12566640
Drug: 5% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sucrose rinse, 5 times daily
Study: 10336571
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg tablet (fasted)
Study: 10336571
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg tablet (fed)
Study: 10336571
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intravenous (i.v.) infusion over 40 min (fasted)
Study: 26216386
Drug: SP3 (S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP3 (S‐1 80 mg/m2/day on days 1‐14 and cisplatin 60 mg/m2 on day 1)
Study: 26216386
Drug: SP5 (S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP5 (S‐1 80‐120 mg/day on days 1‐21 and cisplatin 60 mg/m2 on day 1 or 8)
Study: 19405802
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Local infiltration of port sites with 10 mL of ropivacaine
Study: 19405802
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Infiltration of port sites with 10 mL of ropivacaine and intraperitoneal instillation of 10 mL of ropivacaine
Study: 19405802
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: No analgesic treatment
Study: 15457308
Drug: Self-management (SM)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management (SM) of warfarin using a point-of-care device (Pro Time Microcogulation System)
Study: 15457308
Drug: Physician-management (PM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-management (PM) of warfarin
Study: 11206237
Drug: Fexofenadine and
Normalized name: Fexofenadine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine and montelukast administered concurrently
Study: 9542492
Drug: Ibopamine plus
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine plus prazosin (200 mg single dose)
Study: 336110
Drug: d.1 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d.1 5 hydroxy-tryptophan (600 mg a day)
Study: 28327896
Drug: Infusional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional bleomycin (90,000 units infusion over 72 hours)
Study: 28327896
Drug: Conventional BEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional BEP with weekly bleomycin (30,000 units/week i.v. bolus)
Study: 28327896
Drug: Conventional BEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional BEP with weekly bleomycin
Study: 23236022
Drug: 500 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg/d cyanocobalamin for 8 weeks
Study: 23236022
Drug: 100 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg/d cyanocobalamin for 8 weeks
Study: 23236022
Drug: 10 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/d cyanocobalamin for 8 weeks
Study: 19345767
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine intervention
Study: 15338504
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg qd
Study: 15338504
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg qd
Study: 2738720
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG) 750 mg/kg
Study: 29271278
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU of oral vitamin D3 once weekly)
Study: 27593544
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Ecologic Barrier, Winclove, Amsterdam, The Netherlands) daily for 6 months
Study: 23425142
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment and chlorhexidine body wash (treated carriers)
Study: 23425142
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated carriers)
Study: 23425142
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-carriers)
Study: 20015040
Drug: 11β-HSD1 selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11β-HSD1 selective inhibitors (e.g., DIO-902, INCB13739)
Study: 19100003
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus Hydrochlorothiazide 12.5 mg (TH)
Study: 19100003
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg (T)
Study: 15723265
Drug: Aspirin (acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (acetylsalicylic acid, ASA)
Study: 11853119
Drug: bromperidol (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromperidol (6, 12 or 18 mg/day) for 3 weeks
Study: 30039387
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets alone
Study: 30039387
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets containing vitamin C
Study: 25010824
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy combined with pulsed radiofrequency (PRF) lesioning of the suprascapular nerve (SSN) for 12 weeks.
Study: 25010824
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone for 12 weeks.
Study: 19774311
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (twice a week for 12 weeks)
Study: 16391401
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in SPS
Study: 16391401
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in DM
Study: 16391401
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in IBM
Study: 16391401
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) in SPS
Study: 16391401
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) in DM
Study: 12428313
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion to maintain controlled hypotension with MAP around 60 mmHg
Study: 9709937
Drug: Active/Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active/Placebo patch (AP group)
Study: 9709937
Drug: Active/Active patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active/Active patch (AA group)
Study: 9709937
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (PP group)
Study: 2242951
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (10 capsules, three times daily)
Study: 2242951
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules (10 capsules, three times daily)
Study: 29781315
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic treatment for Staphylococcus aureus (SA) colonization
Study: 29781315
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic treatment
Study: 30017459
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with longitudinal formulation in the first 4 sessions
Study: 27589523
Drug: Bapineuzumab 7
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 7 mg/month
Study: 27589523
Drug: Bapineuzumab 2
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 2 mg/month
Study: 27589523
Drug: Bapineuzumab 20
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab 20 mg/month
Study: 22086119
Drug: Intrasomatic injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAHEPATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasomatic injections of 4 mg/ml of dexamethasone phosphate followed by vertebroplasty
Study: 15496046
Drug: Zinc (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (administered within 24 hours of onset of symptoms)
Study: 15496046
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (administered as a nasal gel)
Study: 8276366
Drug: Flumazenil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (2 mg, intravenous)
Study: 8276366
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml solution, intravenous)
Study: 2657048
Drug: salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: salsalate (3 g/day, adjusted for efficacy and tolerance)
Study: 2657048
Drug: aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (3.6 g/day, adjusted for efficacy and tolerance)
Study: 4613978
Drug: Dapsone, 100
Normalized name: Dapsone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone, 100 mg daily for 14 consecutive days
Study: 4613978
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for the remaining 56 days
Study: 28554928
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (EA) with patient-controlled epidural administration of ropivacaine and sufentanil combined with standard care
Study: 26715476
Drug: 0.05% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% chlorhexidine solution applied twice daily after usual oral hygiene care
Study: 26715476
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no application after usual oral hygiene care
Study: 21190403
Drug: Computer-assisted cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive-behavioral therapy (CBT)
Study: 7266633
Drug: Various antibiotic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antibiotic regimens
Study: 24451151
Drug: Daclatasvir 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 10 mg
Study: 24451151
Drug: Daclatasvir 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 10 mg and 60 mg
Study: 23112909
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of cholecalciferol (vitamin D(3)) for 3 weeks
Study: 11371741
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.05 mg/kg per day)
Study: 9564120
Drug: Long-acting opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting opioid medications
Study: 8034823
Drug: Commitment-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commitment-based intervention (verbal and written commitments for adherence, tasks to increase investment in medication regimen)
Study: 28297591
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement (oral 30 µg ethinyl estradiol or transdermal 100 µg 17‐β‐estradiol patch)
Study: 17211116
Drug: Structured drug
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured drug education program
Study: 12975729
Drug: Semitendinosus and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semitendinosus and gracilis tendon autografts (ST/G)
Study: 3513567
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg folic acid per day
Study: 27013640
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus metronidazole (MTZ) 400 mg TID and amoxicillin (AMX) 500 mg TID for 14 days
Study: 27013640
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus metronidazole (MTZ) and amoxicillin (AMX)
Study: 25012289
Drug: ISIS 329993
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 329993 (ISIS‐CRPR x) at 400 mg
Study: 25012289
Drug: ISIS 329993
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 329993 (ISIS‐CRPR x) at 600 mg
Study: 22449293
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily)
Study: 22449293
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months
Study: 18455592
Drug: Increased cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased cardiac troponin I levels (>0.92 ng/mL)
Study: 18455592
Drug: Increased heart-type
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased heart-type fatty acid-binding protein levels (>6.8 ng/mL)
Study: 15994267
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (FP)
Study: 15994267
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (FP)
Study: 1907840
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium carbonate (500 mg)
Study: 6778757
Drug: intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous fat emulsion (60% of the nonprotein energy) in addition to hypertonic glucose (51.5 +/- 5.0 kcal/kg/day)
Study: 17986818
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received treatment as usual.
Study: 27474496
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (videotapes of EOL and ED encounters)
Study: 22909343
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg after each haemodialysis session
Study: 22909343
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg daily
Study: 15956789
Drug: Modified allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified allergen vaccine (maximum concentration 990 mug/ml, 100 times the maximum dose of native extract)